Mercury Laboratories Limited (BOM:538964)

Market Cap	994.80M
Revenue (ttm)	751.01M
Net Income (ttm)	31.45M
Shares Out	1.20M
EPS (ttm)	26.21
PE Ratio	31.63
Forward PE	n/a
Dividend	3.50 (0.42%)
Ex-Dividend Date	Aug 6, 2025

Volume	6
Average Volume	397
Open	845.00
Previous Close	825.00
Day's Range	829.00 - 845.00
52-Week Range	736.00 - 1,190.00
Beta	0.54
RSI	48.21
Earnings Date	May 27, 2025

About Mercury Laboratories

Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-aller...

• Industry: Pharmaceutical Preparations
• Founded: 1962
• Employees: 482
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 538964

Financial Performance

In 2024, Mercury Laboratories's revenue was 751.01 million, a decrease of -0.61% compared to the previous year's 755.59 million. Earnings were 31.45 million, a decrease of -44.38%.